SEC Tracker
Get the app

Omeros OMER

Omeros grants CEO performance stock option

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. 500,000 shares option granted to CEO
  2. Vesting based on stock price hurdles of $25 to $40
  3. Exercise price set at $17.88 per share
  4. Award expires October 28, 2031

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025